Related Experiment Video
Updated: Jun 5, 2025
Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
Published on: February 14, 2025
Natural killer cells: a new promising source for developing chimeric antigen receptor anti-cancer cells in
Shahrzad Mousavi1, Mohammad Hossein Khazaee-Nasirabadi2, Maryam Sadat Seyedmehdi3
1Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran.
Abstract:
In recent times, the application of CAR-T cell treatment has significantly progressed, showing auspicious treatment outcomes in hematologic malignancies. However, along with these advances, certain limitations and challenges hurdle the widespread utilization of this technology. Recently, CAR-NK cells have gained attention in cancer treatment, as this approach has an important advantage over CART therapy (i.e. no need for HLA matching) for targeting foreign cells. This review aims to explore the benefits of CAR NK cell therapy, and generation strategies, as well as the challenges and limitations hindering the application of CAR NK cells in experimental studies and trials on hematologic malignancies.
Insights
Chimeric antigen receptor (CAR) Natural Killer (NK) cell therapy shows promise for hematologic malignancies, offering advantages over CAR-T cell therapy. This review explores CAR-NK cell benefits, generation, and challenges for broader clinical application.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- CAR-T cell therapy has advanced cancer treatment, particularly for hematologic malignancies.
- Limitations in CAR-T cell therapy hinder its widespread clinical use.
- CAR-NK cells are emerging as a promising alternative with potential advantages.
Purpose of the Study:
- To review the benefits of CAR-NK cell therapy.
- To explore CAR-NK cell generation strategies.
- To identify challenges and limitations of CAR-NK cell therapy in hematologic malignancies.
Main Methods:
- Literature review of experimental studies and clinical trials.
- Analysis of CAR-NK cell generation protocols.
- Evaluation of therapeutic efficacy and safety data.
Main Results:
- CAR-NK cells offer advantages such as allogeneic potential and reduced graft-versus-host disease risk.
- Various strategies exist for CAR-NK cell generation, including genetic modification and co-culture methods.
- Challenges include optimizing in vivo persistence, efficacy, and overcoming the tumor microenvironment.
Conclusions:
- CAR-NK cell therapy holds significant potential for treating hematologic malignancies.
- Further research and clinical trials are needed to overcome existing challenges.
- CAR-NK cells may offer a more accessible and versatile immunotherapy option.
